Neurocrine Biosciences' INGREZZA® Shows Promise in Huntington's Disease Management

New Developments in Huntington's Disease Management: Neurocrine Biosciences’ INGREZZA® Shows Promise

Neurocrine Biosciences, Inc. has recently showcased significant advancements in the treatment of Huntington's disease through its once-daily medication, INGREZZA® (valbenazine), during the 2025 MDS International Congress of Parkinson's Disease and Movement Disorders. The KINECT®-HD2 study reveals that INGREZZA effectively manages chorea severity in adults over a three-year trial involving 154 participants. Results indicate early and sustained improvements in chorea symptoms, as evidenced by notable reductions in the Unified Huntington's Disease Rating Scale (UHDRS) Total Maximal Chorea (TMC) score. By the end of Week 2, participants receiving the 40 mg dosage exhibit a mean improvement of -3.4±0.3, with continuous enhancements reported through Week 156.

The patient response rates further highlight the efficacy of INGREZZA. At Week 2, 34.5% of participants report an improvement according to the Patient Global Impression of Change (PGI-C), a figure that rises to 75.9% by Week 104, and maintains at 77.8% by Week 156. These findings underscore the treatment's potential to significantly enhance the quality of life for individuals afflicted with Huntington's disease while demonstrating a tolerable safety profile. Notably, the study confirms that the concomitant use of antipsychotic medications does not adversely affect the management of chorea, a key consideration for many patients who may require multiple therapeutic interventions.

Dr. Sanjay Keswani, Chief Medical Officer of Neurocrine Biosciences, emphasizes the impact of these findings, particularly given the debilitating nature of chorea. The long-term efficacy and safety profile of INGREZZA suggests that it offers hope for sustained symptom relief among those suffering from Huntington's disease. With these compelling results, Neurocrine positions itself at the forefront of innovative treatments, enhancing the potential for improved patient outcomes in a field that has limited options.

In addition to these promising developments, Neurocrine Biosciences announces the appointment of Mike Sibley as Senior Vice President and General Manager of its Neuropsychiatry franchise, effective October 6, 2025. Sibley, who brings over two decades of experience in the biopharmaceutical industry, will lead the sales and marketing strategy for Neurocrine’s neuropsychiatry products, including the INGREZZA franchise. His extensive background, including significant roles at Sanofi and Galderma Laboratories, positions him well to drive growth and innovation within the company’s product offerings.

Neurocrine remains committed to discovering and developing transformative treatments for neurological, neuroendocrine, and neuropsychiatric disorders. With a diverse portfolio of FDA-approved therapies and an array of compounds in clinical development, the company continues its mission to alleviate the burden of debilitating diseases through innovative science.